AAO 2020: Preventing cystoid macular oedema after cataract surgery

By OTE Staff Reports
Conference|AAO

Rudy Nuijts of the University Eye Clinic Maastricht, the Netherlands, discusses the highlights of his AAO 2020 presentation on a combination treatment regimen for lowering the incidence of cystoid macular oedema following category surgery.


Rudy Nuijts of the University Eye Clinic Maastricht, the Netherlands, discusses the highlights of his AAO 2020 presentation on a combination treatment regimen for lowering the incidence of cystoid macular oedema following category surgery.

Related Videos
View All
Related Content

Ocuphire announces topline results from ZETA-1 phase 2 trial of APX3330 in diabetic retinopathy

January 26th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Using gene therapy to target Usher Syndrome Type 2A

January 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Coherus BioSciences acquiring exclusive US commercial rights to aflibercept biosimilar

January 23rd 2023

In settlement, Arizona eye surgery network to pay $1 million, end discriminatory policies towards patients with disabilities

January 21st 2023

Ocuphire announces topline results from ZETA-1 phase 2 trial of APX3330 in diabetic retinopathy

January 26th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Using gene therapy to target Usher Syndrome Type 2A

January 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Coherus BioSciences acquiring exclusive US commercial rights to aflibercept biosimilar

January 23rd 2023

In settlement, Arizona eye surgery network to pay $1 million, end discriminatory policies towards patients with disabilities

January 21st 2023

Ocuphire announces topline results from ZETA-1 phase 2 trial of APX3330 in diabetic retinopathy

January 26th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Using gene therapy to target Usher Syndrome Type 2A

January 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Coherus BioSciences acquiring exclusive US commercial rights to aflibercept biosimilar

January 23rd 2023

In settlement, Arizona eye surgery network to pay $1 million, end discriminatory policies towards patients with disabilities

January 21st 2023
Advertise
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.